MALVERN, PA — Endo, a subsidiary of Mallinckrodt plc, has expanded its ADRENALIN® line with the launch of three new FDA-approved premixed intravenous (IV) bag concentrations: 2 mg/250 mL, 5 mg/250 mL, and 10 mg/250 mL.
With this addition, the company now offers ADRENALIN® premixed IV bags in five concentrations, including the 5 mg and 10 mg doses that align with the American Society of Health-System Pharmacists (ASHP) Standardize 4 Safety Initiative. The move underscores industry efforts to reduce medication errors and improve patient safety.
ADRENALIN® remains the first and only FDA-approved, commercially available manufacturer-prepared epinephrine premixed IV bag, providing a ready-to-use solution designed to ease hospital workflows.
“We’re proud to support hospital teams with ready-to-use medicines that help make care easier and more efficient,” said Scott Sims, Senior Vice President and General Manager of Endo Injectable Solutions and Generics. “We’re excited to grow our TruDelivery® portfolio and give providers more options to focus on what matters most–caring for patients.”
The new formulations are indicated to increase mean arterial blood pressure in adults with hypotension tied to septic shock. Key features include no compounding or preparation, a single-port IV design to reduce risks of inadvertent mixing, and a 24-month room temperature shelf life.
Part of Endo’s TruDelivery® platform, the premixed IV bags are intended to streamline hospital operations, cut waste, lower costs, and reduce preparation errors while supporting consistent, high-quality patient care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.